Tangshen Formula Treatment for Diabetic Kidney Disease by Inhibiting Racgap1-stat5-Mediated Cell Proliferation and Restoring miR-669j-Arntl-Related Circadian Rhythm

ADEF 1 Xiuying Wang
BF 2 Hai Zhao
BDF 3 Xingquan Wu
BCD 1 Guangsheng Xi
ADE 1 Shengxue Zhou

Corresponding Author: Shengxue Zhou, e-mail: zhoushengxue1111@163.com
Source of support: This study was supported by the Chinese Medicine Key Advantages Program of the Provincial Subjects of Jilin Agricultural Science and Technology College in Jilin province

Background: The aim of this study was to investigate the underlying mechanisms of Tangshen formula (TSF) for treatment of diabetic kidney disease (DKD).

Material/Methods: Microarray dataset GSE90842 was collected from the Gene Expression Omnibus database, including renal cortical tissues from normal control (NC), DKD, and DKD mice given TSF for 12 weeks (TSF) (n=3). Differentially-expressed genes (DEGs) were identified using LIMMA method. A protein-protein interaction (PPI) network was constructed using data from the STRING database followed by module analysis. The Mirwalk2 database was used to predict the underlying miRNAs of DEGs. Function enrichment analysis was performed using the DAVID tool.

Results: A total of 2277 and 2182 genes were identified as DEGs between DKD and NC or TSF groups, respectively. After overlap, 373 DEGs were considered as common in 2 comparison groups. Function enrichment indicated common DEGs were related to cell proliferation (Asf1b, anti-silencing function 1B histone chaperone; Anln, anillin, actin-binding protein; Racgap1, Rac GTPase activating protein 1; and Stat5, signal transducer and activator of transcription 5) and circadian rhythm (Arntl, aryl hydrocarbon receptor nuclear translocator-like). Racgap1 was considered as a hub gene in the PPI network because it could interact with Asf1b, Anln, and Stat5. Arntl was regulated by miR-669j in the miRNA-DEGs network and this miRNA was also a DEG in 2 comparisons.

Conclusions: TSF may be effective for DKD by inhibiting Racgap1-stat5-mediated cell proliferation and restoring miR-669j-Arntl-related circadian rhythm.

MeSH Keywords: Cell Proliferation • Circadian Rhythm • Diabetic Nephropathies • MicroRNAs

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/907412

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Background

Diabetes is the third most common chronic disease worldwide (after cancer and cardiovascular diseases) and is associated with economic development. According to the International Diabetes Federation, 366 million people had diabetes in 2011 and this will reach 552 million by year 2030 [1]. China is one of the countries with the largest numbers of people with diabetes (90.0 million in 2011 and 129.7 million by 2030) [1]. Diabetic kidney disease (DKD) is the most prevalent and serious microvascular complication following diabetes. It is estimated that DKD is developed concomitantly in more than 60% of persons with diabetes [2]. Persistent albuminuria/proteinuria excretion indicates kidney function is damaged. DKD is difficult to reverse and easily progresses to chronic renal failure and end-stage renal disease, ultimately resulting in disability or death [3]. Thus, diabetes-associated DKD has become a significant public health problem that needs to be addressed.

Currently, DKD can be managed by glycemic control, antihypertensive drugs (angiotensin-converting enzyme, angiotensin receptor blocker, and calcium channel blocker) and antilipemic agents [4–6]. Although all these treatments seem to be effective, adverse reactions (e.g., hypotension, hyperkalemia, renal, urinary and respiratory disorders) after long-term use have been well documented [7,8]. Thus, investigation of more effective and safe treatment strategies is a clinically important issue.

Compared with target-oriented Western medicine, Traditional Chinese Medicine (TCM) maintains the body’s normal function or homeostasis based on a holistic and synergistic theory to restore the balance of Yin-Yang of body energy [9]. In addition, TCM uses a combination of plants, minerals, and animal parts for treatment of diseases, several of which are medicinal and edible, inducing few adverse effects [10]. Therefore, TCM treatment is suggested as an effective and safe alternative for treatment of DKD [10,11]. Tangshen formula (TSF) is a commonly prescribed Chinese herbal medicine for diabetic renal injuries. A recent prospective, multicenter, double-blind, randomized, controlled study has demonstrated the significant benefit of TSF in decreasing proteinuria and improving estimated glomerular filtration rate in DKD patients compared with placebo [12]. Further studies indicate TSF may attenuate DKD by inhibiting zinc finger and BTB domain containing 16 (ZBTB16/PLZF) expression [13], transforming growth factor receptor blocker, and calcium channel blocker) and antilipemic agents [4–6]. Although all these treatments seem to be effective, adverse reactions (e.g., hypotension, hyperkalemia, renal, urinary and respiratory disorders) after long-term use have been well documented [7,8]. Thus, investigation of more effective and safe treatment strategies is a clinically important issue.

Data normalization and DEGs identification

The raw CEL files were preprocessed and normalized using the Robust Multichip Average (RMA) algorithm [16] in the R Bioconductor package (http://www.bioconductor.org/packages/release/bioc/html/affy.html). The DEGs between DKD and NC/TSF group were screened using the Linear Models for Microarray data (LIMMA) method [17] in the Bioconductor R package (http://www.bioconductor.org/packages/release/bioc/html/limma.html). The cutoff point of |logFC| >0.5 was set to obtain more DEGs. A heatmap of DEGs was constructed using R package pheatmap (http://cran.r-project.org/web/packages/pheatmap/index.html). A Venn diagram was constructed to screen the DEGs between DKD and NC groups that were reversed by TSF treatment using an online tool (http://bioinformatics.psb.ugent.be/webtools/Venn/).

Material and Methods

Microarray data

Microarray dataset GSE90842 was downloaded from NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/), which included renal cortical tissue samples from 20-week-old male C57BLKS/J db/m mice (normal control group, NC, n=3), 20-week-old male C57BLKS/J db/db mice (DKD group, n=3), and db/db mice given TSF by intra-gastric gavage (2.4 g/kg/day) for 12 weeks (TSF group, n=3). The non-treatment mice were administered saline. Experiments were approved by the Ethics Committee of the China-Japan Friendship Institute of Clinical Medical Sciences and performed in accordance with the NIH Guiding Principles for the Care and Use of Laboratory Animals [13].
PPI network construction

The DEGs were mapped into the PPI data retrieved from the STRING 10.0 (Search Tool for the Retrieval of Interacting Genes; http://string-db.org/) database [18] to construct the PPI network, with the threshold value set as the combined scores >0.9. The PPI network was visualized using Cytoscape software 2.8 (www.cytoscape.org/) [19]. The hub genes with more interactions with other genes (degree) were selected and plotted with ggplot2 in R package (http://www.R-project.org/). To identify functionally related and highly interconnected clusters from the PPI network, module analysis was then conducted using the Molecular Complex Detection (MCODE) plugin of Cytoscape software. The parameters were set as: degree cutoff=6, node score cutoff=0.2, k-core=5, and maximum depth=100 (ftp://ftp.mshri.on.ca/pub/BIND/Tools/MCODE) [20]. Modules with MCODE score ≥4 and nodes ≥6 were considered significant.

miRNA prediction

The DEGs-related miRNAs were predicted using the Mirwalk2 database (http://www.zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2) [21], which provides the largest collection of predicted and experimentally verified miR-target interactions with various miRNA databases. Then, the miRNA-target gene interaction network was constructed and visualized using Cytoscape software 2.8 (www.cytoscape.org/) [19].

Function enrichment analysis

Kyoto encyclopedia of genes and genomes (KEGG) pathway and Gene ontology (GO) enrichment analyses were carried out to explore the underlying functions of all DEGs and genes in PPI network and modules using the Database for Annotation, Visualization and Integrated Discovery (DAVID) 6.8 online tool (http://david.abcc.ncifcrf.gov). P<0.05 was set as the threshold to screen the significant GO biological process (BP) terms and KEGG.

Screening of small-molecule drugs similar to TSF treatment

The Connectivity Map (CMAP, http://www.broadinstitute.org/cmap/), which contains more than 7000 expression signatures involving 6100 small molecules as treatment-control pairs, was used to compare the DEGs with genes perturbed by small molecules in the CMAP database, to identify underlying drugs associated with these DEGs. A correlation score for each corresponding small molecule was calculated, ranging from −1 to 1. A high positive connectivity score (close to +1) indicates that the corresponding small molecule induced the expression of the query signature, while a high negative connectivity score (close to −1) indicates that the corresponding small molecule reversed the expression of the query signature. Significant small-molecule drugs were selected according to the threshold value of p<0.05 and [mean] >0.4.

Results

Identification of DEGs

According to the threshold of p<0.05 and |logFC| >0.1, there were 2277 genes identified as DEGs between NC and DKD groups, including 1138 upregulated and 1139 downregulated genes, while 2182 genes were identified as DEGs between TSF and DKD groups, including 1152 upregulated and 1130 downregulated genes. The clustering analysis in heatmap indicated that the identified DEGs perform well in distinguishing between the 2 groups (Figure 1).

Further, a Venn diagram was used to obtain the overlap of the upregulated (downregulated) DEGs between NC and DKD with the downregulated (upregulated) DEGs between TSF and DKD (i.e., the DEGs changed in DKD can be reversed by TSF). As a result, 193 common DEGs (including 4 miRNAs) were identified between the upregulated DEGs of NC and DKD comparison and the downregulated DEGs of TSF and DKD comparison (defined as downregulated), while 180 common DEGs (including 14 miRNAs) were identified between downregulated DEGs of NC and DKD comparison and the upregulated DEGs of TSF and DKD comparison (defined as upregulated) (Figure 2, Table 1).

Function enrichment analysis for common DEGs

The potential functions of all common DEGs were predicted by the online tool DAVID. As a result, 12 GO BP terms and 7 KEGG pathways were enriched for DEGs. The GO BP terms mainly included transcription, DNA-templated (antisilencing function 1B histone chaperone, Asf1b: logFC=0.62, p-value=6.71E-03, NC vs. DKD; logFC=−0.38, p-value=5.93E-03, TSF vs. DKD), positive regulation of cell proliferation (Stat5a: logFC=−0.39, p-value=3.35E-03, NC vs. DKD; logFC=0.27, p-value=5.43E-03, TSF vs. DKD) and cell division (anillin, actin-binding protein, Anln: logFC=0.80, p-value=4.76E-03, NC vs. DKD; logFC=−0.46, p-value=3.85E-02, TSF vs. DKD; Rac GTPase activating protein 1, Racgap1: logFC=0.44, p-value=1.81E-03, NC vs. DKD; logFC=−0.18, p-value=2.80E-02, TSF vs. DKD; cell division cycle 25B, Cdc25b: logFC=0.23, p-value=4.98E-02, NC vs. DKD; logFC=−0.30, p-value=1.80E-02, TSF vs. DKD), while the enriched KEGG pathways were nerve conduction-related, including neuroactive ligand-receptor interaction and cholinergic synapse (cholinergic receptor muscarinic 1, Chrm1: logFC=−0.23, p-value=2.368E-02, NC vs. DKD; logFC=0.18, p-value=2.72E-02, TSF vs. DKD) (Table 2).
A PPI network was constructed to screen crucial genes associated with TSF treatment, including 106 nodes (59 upregulated and 47 downregulated) and 143 edges (interaction relationships) (Figure 3). After calculating the degree, Racgap1 (degree=12), Asf1b (degree=9) and Anln (degree=6) were found to be hub genes (Figure 3). In addition to regulation of cell proliferation, cell cycle, and nerve conduction, the DEGs in PPI were also involved in circadian rhythm (aryl hydrocarbon receptor nuclear translocator-like, Arntl: logFC=–1.01, p-value=3.81E-02, NC vs. DKD; logFC=0.62, p-value=3.96E-02, TSF vs. DKD) (Table 3).

Further, 1 significant module was screened from the PPI network (Figure 4), which was also enriched into cell division- and cell cycle-related GO terms (without no pathways enriched), demonstrating these processes may be especially important mechanisms for TSF treatment (Table 4).

### DEGs-related miRNAs

After searching the Mirwalk2 database, 145 miRNAs were found to regulate the above common DEGs, which was used to construct a miRNA-DEGs network, including 181 interaction pairs and 24 DEGs. As shown in Figure 5, Asf1b and Anln were regulated by mmu-miR-703, which was significantly upregulated in DKD compared with NC (logFC=0.59, p-value=1.46E-02); Arntl was regulated by mmu-miR-669j, which was a DEG in...
Figure 2. Heat map showing all common differentially-expressed genes between DKD vs. NC and DKD vs. TSF. NC – normal control; DKD – diabetic kidney disease; TSF – Tangshen formula. High-level expression is indicated by red and low-level expression is indicated by green.
| Gene        | LogFC | P-value | LogFC | P-value |
|-------------|-------|---------|-------|---------|
| Mir145      | 0.67  | 5.13E-03| -0.72 | 6.61E-05|
| Palld       | 0.24  | 1.67E-02| -0.53 | 2.48E-04|
| Serpinb8    | 0.69  | 3.11E-05| -0.62 | 2.49E-04|
| Sirpb1a     | 0.45  | 1.84E-05| -0.65 | 4.66E-04|
| Bmp5        | 0.46  | 3.83E-03| -0.61 | 5.2E-04 |
| Sprr1a      | 1.66  | 3.73E-04| -1.01 | 5.41E-04|
| Ces1c       | 0.39  | 3.92E-02| -0.70 | 6.22E-04|
| Ifit2       | 0.47  | 2.67E-02| -0.41 | 8.46E-04|
| Gils2       | 0.21  | 4.92E-02| -0.41 | 8.46E-04|
| Smc2        | 0.53  | 2.70E-03| -0.31 | 9.46E-04|
| 4931414P19Rik | 0.33   | 6.16E-03| -0.40 | 9.71E-04|
| Htr1e       | 0.50  | 9.87E-04| -0.41 | 1.27E-03|
| Prc1        | 0.60  | 4.03E-03| -0.44 | 1.33E-03|
| Stard4      | 0.59  | 1.61E-02| -0.35 | 1.34E-03|
| Duspa2      | 0.40  | 3.54E-03| -0.35 | 1.61E-03|
| 2610008E11Rik | 0.57    | 1.26E-02| -0.33 | 1.61E-03|
| Upk2        | 0.44  | 2.48E-02| -0.51 | 1.70E-03|
| Htr1a       | 0.55  | 9.87E-04| -0.41 | 1.27E-03|
| Tnfsf15     | 0.37  | 1.51E-02| -0.63 | 1.93E-03|
| Gm19846     | 0.37  | 4.17E-03| -0.36 | 2.05E-03|
| Gce4        | -0.85 | 1.78E-01| 0.23  | 4.79E-02|
| Scl25a18    | -0.39 | 3.58E-04| 0.43  | 5.75E-04|
| Gzmk        | -0.55 | 1.13E-02| 0.29  | 2.49E-02|
| Strn1       | -0.37 | 1.22E-03| 0.26  | 3.80E-02|
| Mir1905     | -0.53 | 1.35E-03| 0.21  | 4.86E-02|
| Pk5         | -0.48 | 1.52E-03| 0.44  | 9.33E-04|
| Gm20208     | -0.35 | 5.33E-03| 0.23  | 6.76E-03|
| Olf1272     | -0.59 | 1.57E-03| 0.30  | 6.77E-03|
| A730085A09Rik | -0.49     | 1.81E-03| 0.29  | 2.50E-02|
| Gm7241      | -0.47 | 2.48E-03| 0.85  | 7.62E-04|
| Neurog2     | -0.60 | 2.67E-03| 0.27  | 3.79E-02|
| Mir1956     | -0.52 | 2.68E-03| 0.60  | 1.34E-03|
| Gm12        | -0.32 | 2.69E-03| 0.30  | 4.85E-03|
| Htx1        | -0.45 | 2.69E-03| 0.29  | 7.65E-03|
| Mamld1      | -0.60 | 3.10E-03| 0.47  | 7.45E-03|
| Plscr5      | -0.30 | 3.22E-03| 0.19  | 2.02E-02|
| Ghrhr       | -0.42 | 3.64E-04| 0.33  | 2.51E-03|

NC – normal control; DKD – diabetic kidney disease; TSF – Tangshen formula; FC – fold change.
Table 2. Significantly enriched functions for all differentially expressed genes.

| Term                                                      | P-value | Genes                                                                 |
|-----------------------------------------------------------|---------|-----------------------------------------------------------------------|
| GO: 0006355—regulation of transcription, DNA-templated     | 3.95E-06| STAT5A, PHF20, ZFP788, ZFP873, ZFP879, ASF1B, NEUROG2, ABCG1, PP1E, MAML1, ... |
| GO: 0006357—regulation of transcription from RNA polymerase II promoter | 4.25E-03| CAMTA2, STAT5A, GLIS2, BARH1L2, TCEAL6, MYBL1, HES6, MED4, MAML1, TCEA2, ... |
| GO: 0060124—positive regulation of growth hormone secretion| 6.50E-03| GABBR1, GHR1, GHRHR                                                   |
| GO: 0045165—cell fate commitment                           | 1.24E-02| ERBB4, ONECUT2, BARH1L2, NEUROG2, SOX8                               |
| GO: 0008284—positive regulation of cell proliferation      | 1.84E-02| SSBP3, SHMT2, ERBB4, PRC1, STAT5A, CAMP, BTC, EFNB2, PROX1, GHRHR, ... |
| GO: 0030512—negative regulation of transforming growth factor beta receptor signaling pathway | 2.96E-02| ASPN, PEG10, ONECUT2, PPM1A                                           |
| GO: 0055005—ventricular cardiac myofibril assembly         | 3.69E-02| NKX2-5, PROX1                                                          |
| GO: 006351—transcription, DNA-templated                    | 4.31E-02| STAT5A, ONECUT2, PHF20, MYBL1, SOX8, TAL2, ZFP879, HNRNPD, TCEA2, ASF1B, ... |
| GO: 0051301—cell division                                 | 4.51E-02| KIF5C5B, PLK5, PRC1, NCAPG2, SPAG5, KATNB1, ANLN, RACGAP1, SMC2, CDC25B |
| GO: 0060024—rhythmic synaptic transmission                | 4.89E-02| NLGN3, CACNA1A                                                         |
| GO: 000255—allantoin metabolic process                    | 4.89E-02| STAT5A, ALLC                                                          |
| mmu04024: cAMP signaling pathway                          | 4.47 E-03| HTR1B, VAV3, CHRM1, GABBR1, GHR1, GRIA3, VIPR2, CACNA1D               |
| mmu04080: Neuroactive ligand-receptor interaction         | 9.74E-03| HTR1B, SSTR3, CHRM1, GABBR1, CHRN4, GRIA3, NMBR, VIPR2, GHRHR         |
| mmu04727: GABAergic synapse                               | 1.30E-02| SLC38A2, GABBR1, GN3, CACNA1D, CACNA1A                               |
| mmu04725: Cholinergic synapse                             | 3.06E-02| CHRM1, CHRN4, GN3, CACNA1D, CACNA1A                                  |
| mmu04724: Glutamatergic synapse                           | 3.23E-02| SLC38A2, GRIA3, GN3, CACNA1D, CACNA1A                                |
| mmu04010: MAPK signaling pathway                          | 4.92E-02| MAP3K6, FGF11, PPM1A, CACNA1D, MAP3K12, CACNA1A, CDC25B              |
| mmu04726: Serotonergic synapse                            | 4.96E-02| HTR1B, SLC6A4, GN3, CACNA1D, CACNA1A                                  |

The genes were enriched into Gene ontology (GO) biological process terms and Kyoto encyclopedia of genes and genomes (KEGG) pathways. The genes were differentially expressed between NC and DKD, and significantly reversed by TSF treatment. NC – normal control; DKD – diabetic kidney disease; TSF – Tangshen formula.

2 comparisons (logFC=0.35, p-value=1.13E-02, NC vs. DKD; logFC=−0.40, p-value=1.11E-02, TSF vs. DKD).

**Small-molecule drugs similar to TSF treatment**

The DEGs, including 180 upregulated and 193 downregulated DEGs, were analyzed by use of the CMAP tool. As a result, 37 small-molecule chemicals with positive mean and enrichment scores were predicted, including thioguanosine, withaferin-A, DL-thiorphan, and menadione, which indicated their potential similarity to TSF for treatment of DKD, and these may exert a synergistic effect (Table 5).

**Discussion**

Compared the study of Zhao et al. [13], more DEGs were screened between NC vs. DKD (2277 vs. 83) and TSF vs. DKD (2182 vs. 13) using the non-strict threshold in our present study, which led to more overlap among 2 comparisons (373 vs. 3, Pgm5, Zbtb16/PLZF, and Abcb1b). Although Pgm5 (phosphoglucomutase 5), Zbtb16/PLZF, and Abcb1b [ATP-binding cassette, sub-family B (MDR/TAP), member 1B] identified by Zhao et al. [13] were also found in our study, subsequent PPI network and topological property analysis excluded their importance (Pgm5, degree=1; Zbtb16/PLZF, degree=0; Abcb1b, degree=3). On the
Figure 3. Protein-protein interaction network to screen crucial genes. (A) Protein-protein interaction network of differentially-expressed genes of overlap between DKD and NC/TSF. Upregulated genes are indicated by orange and downregulated genes are indicated by green. (B) Protein rank according their interaction pairs in the protein-protein interaction network.

Table 3. Significantly enriched functions for differentially expressed genes of PPI network.

| Term                                                                 | P-value   | Genes                                                                 |
|----------------------------------------------------------------------|-----------|------------------------------------------------------------------------|
| GO: 0008284–positive regulation of cell proliferation                | 7.10E-04  | SSBP3, SHMT2, PRC1, ERBB4, STAT5A, BTC, EFNB2, HBEGF, NNX2-5, PROX1, GHRHR |
| GO: 0060124–positive regulation of growth hormone secretion         | 1.27E-03  | GABBR1, GHRL, GHRHR                                                   |
| GO: 0051301–cell division                                          | 4.23E-03  | KIFCS5B, PRC1, NCAPG2, SPAG5, ANLN, RACGAP1, SMC2, CDC25B               |
| GO: 0006357–regulation of transcription from RNA polymerase II promoter | 5.83E-03  | MED4, GLIS2, STAT5A, MYBL1, HES6, TCEA2, NNX2-5, SIM1                  |
| GO: 0007165–signal transduction                                     | 7.61E-03  | GNAZ, STAT5A, GABBR1, RACGAP1, VIPR2, GHRHR, HTR1B, SSTR3, CHRM1, GNB3 |
| GO: 0007188–adenylate cyclase-modulating G-protein coupled receptor signaling pathway | 1.46E-02  | GNAZ, CACNA1D, GHRHR                                                   |
| GO: 0055005–ventricular cardiac myofibril assembly                  | 1.62E-02  | NNX2-5, PROX1                                                          |
| GO: 0045944–positive regulation of transcription from RNA polymerase II promoter | 1.87E-02  | SSBP3, MSX1, GLIS2, STAT5A, LEO1, NEUROG2, MYBL1, TCEA2, ARNTL, NNX2-5, PROX1, BMP5 |
| GO: 0006355–regulation of transcription, DNA-templated              | 1.92E-02  | STAT5A, GLIS2, NEUROG2, MYBL1, ARNTL, HES6, PROX1, TAL2, PPIE, ASF1B... |
| GO: 0007623–circadian rhythm                                        | 2.09E-02  | SLC6A4, ARNTL, BHLHE41, PROX1                                         |
| GO: 0035556–intracellular signal transduction                       | 2.16E-02  | SIRPB1A, HUNK, LAT, STK32B, VAV3, RACGAP1, GSG2                       |
| GO: 0046426–negative regulation of JAK-STAT cascade                 | 2.27E-02  | ASPN, RTN4RL1, RTN4R                                                   |
Table 3 continued. Significantly enriched functions for differentially expressed genes of PPI network.

| Term                                                                 | P-value    | Genes                                      |
|----------------------------------------------------------------------|------------|--------------------------------------------|
| GO: 0006351—transcription, DNA-templated                             | 2.43E-02   | STAT5A, GLI52, NEUROG2, MYBL1, ARNTL, HES6, PROX1, TAL2, MED4, ASF1B… |
| GO: 0007193—adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway | 2.47E-02   | GNAZ, HTR1B, GABBR1                       |
| GO: 0007595—lactation                                               | 2.58E-02   | ERBB4, STAT5A, GHRHR                     |
| GO: 0048511—rhythmic process                                       | 3.24E-02   | HNRNPD, ARNTL, BHLHE41, PROX1            |
| GO: 0045893—positive regulation of transcription, DNA-templated     | 3.70E-02   | SSBP3, MED4, ERBB4, GLI52, PPM1A, ARNTL, NKX2-5, PROX1 |
| GO: 0051988—regulation of attachment of spindle microtubules to kinetochore | 3.73E-02   | SPAG5, RACGAP1                           |
| GO: 0002591—positive regulation of antigen processing and presentation of peptide antigen via MHC class I | 3.73E-02   | ABCB1A, ABCB1B                           |
| GO: 002489—antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-dependent | 0.042553   | ABCB1A, ABCB1B                           |
| GO: 0019221—cytokine-mediated signaling pathway                     | 4.50E-02   | ASPN, RTN4L1, STAT5A, RTN4R              |
| GO: 0048845—venous blood vessel morphogenesis                       | 4.77E-02   | EFNB2, PROX1                              |
| GO: 0046010—positive regulation of circadian sleep/wake cycle, non-REM sleep | 4.77E-02   | GHRL, GHRHR                              |
| GO: 0002485—antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-dependent | 4.77E-02   | ABCB1A, ABCB1B                           |
| GO: 0002481—antigen processing and presentation of exogenous protein antigen via MHC class I via ER pathway, TAP-dependent | 4.77E-02   | ABCB1A, ABCB1B                           |
| GO: 0030816—positive regulation of cAMP metabolic process           | 4.77E-02   | CHGA, GHRHR                              |
| GO: 0007049—cell cycle                                             | 4.92E-02   | PRC1, NCAPG2, SPAG5, ANLN, RACGAP1, SMC2, GSG2, CDC25B |
| mmu04024: cAMP signaling pathway                                    | 1.60E-03   | HTR1B, VAV3, CHRM1, GABBR1, GHRL, VIPR2, CACNA1D |
| mmu04080: Neuroactive ligand-receptor interaction                    | 2.22E-03   | HTR1B, SSTR3, CHRM1, GABBR1, CHRN4B, NMBR, VIPR2, GHRHR |
| mmu04725: Cholinergic synapse                                        | 5.972E-03  | CHRM1, CHRN4B, GN3, CACNA1D, CACNA1A    |
| mmu04726: Serotonergic synapse                                       | 1.02E-02   | HTR1B, SLC6A4, GN3, CACNA1D, CACNA1A    |
| mmu04012: ErbB signaling pathway                                    | 1.85E-02   | ERBB4, STAT5A, B7C, HBEFG                |
| mmu04727: GABAergic synapse                                         | 1.85E-02   | GABBR1, GN3, CACNA1D, CACNA1A           |

The genes were enriched into Gene ontology (GO) biological process terms and Kyoto encyclopedia of genes and genomes (KEGG) pathways. The genes were differentially expressed between NC and DKD, and significantly reversed by TSF treatment. NC – normal control; DKD – diabetic kidney disease; TSF – Tangshen formula.
contrary, we preliminarily identified that Racgap1 (degree=12), Asf1b (degree=9), Anln (degree=6), and Stat5a (degree=4) were particularly important. Asf1b, Anln, and Racgap1 were significantly upregulated in DKD but were downregulated by TSF treatment, while the opposite result was observed for Stat5a, which was downregulated in DKD but upregulated after TSF treatment. These genes were enriched into cell growth (Asf1b, Anln, Racgap1, and Stat5). Arntl, which had a similar expression pattern to Stat5a, was considered to be pivotal because of its involvement in circadian rhythm, a specific pathway enriched by the genes in PPI. Accordingly, we believe TSF may be effective for treatment of DKD by the above pathways, which appears to be in line with previous studies directly or indirectly as shown by the following evidence.

It is widely accepted that glomerular mesangial expansion is one of the main pathologic characteristics of DKD, which develops due to mesangial cell proliferation and excessive accumulation of extracellular matrix (ECM) proteins [22–24]. Thus, suppressing cell growth to manage DKD has been extensively investigated in recent years [22–24]. In the present study we showed that TSF may also be effective for DKD by this mechanism because the related genes have been demonstrated to be associated with cell proliferation. It has been reported that depletion of histone H3–H4 chaperone Asf1b severely compromises proliferation, leading to aberrant nuclear structures and a distinct transcriptional signature, while its overexpression increases cellular proliferation, promoting tumor progression and predicting poor outcomes [25]. This effect of Asf1b was also observed in β cell proliferation [26]. Anln is an actin-binding protein required for cytokinesis. Similarly, several studies have proved Anln plays a critical role in human carcinogenesis and serves as a poor prognostic biomarker [27,28]. Knockdown of Anln by lentivirus results in G2/M phase arrest, cell growth, and migration inhibition, achieving the treatment goal for cancer [28,29]. Racgap1 is a component of the central spindle protein complex and is also essential for orchestrating cell division. Thus, its upregulated expression increases the potential of cell excessive proliferation and induces cancer [30]. However, there were no studies focusing on their roles (Cdc25b, Asf1b, Anln, and Racgap1) in DKD and they may be novel targets, which require further experiments to confirm.

Although the study of Hu et al. [15] has demonstrated TSF may be beneficial for DKD treatment via regulating the JAK/STAT/SOCS signaling pathway, only the expressions of Stat3 (upregulated) and Stat4 (downregulated) were detected. Stat5 was also upregulated after TSF in our study, indicating similar function to Stat3. Furthermore, a recent study indicates Racgap1 appears to be involved cytokinesis by translocation of Stat3. Both Racgap1 inhibitor and siRNA-mediated silencing treatment resulted in increased Stat3 phosphorylation and STAT3-driven transcriptional activity [31]. Thus, we speculated there was also an interaction between Racgap1 and Stat5, which was demonstrated in our PPI network. Also, Racgap1 was observed

| Term | Count | P-value | Genes |
|------|-------|---------|-------|
| GO: 0051301~cell division | 6 | 2.17E-08 | PRC1, NCAPG2, SPAG5, ANLN, RACGAP1, SMC2 |
| GO: 0007049~cell cycle | 6 | 2.59E-07 | PRC1, NCAPG2, SPAG5, ANLN, RACGAP1, SMC2 |
| GO: 00007067~mitotic nuclear division | 4 | 6.87E-05 | NCAPG2, SPAG5, ANLN, SMC2 |
| GO: 0051988~regulation of attachment of spindle microtubules to kinetochore | 2 | 2.32E-03 | SPAG5, RACGAP1 |
| GO: 0030261~chromosome condensation | 2 | 5.30E-03 | NCAPG2, SMC2 |
| GO: 0000281~mitotic cytokinesis | 2 | 9.92 E-03 | ANLN, RACGAP1 |
to interact with Anln and Asf1b. Therefore, Racgap1 may be an especially pivotal target in the treatment of TSF for DKD.

Normal circadian rhythms are crucial for maintaining physiological and functional homeostasis; once disrupted, pathological diseases may be triggered, such as diabetes [32]. Several studies have demonstrated the expression of clock (Per1, Period circadian clock 1; Per2; Arntl; CLOCK, circadian locomotor output cycles kaput; Cry1, cryptochrome 1), as well as clock-controlled genes (Dbp, D site albumin promoter binding protein; E4bp4, also known as NFIL3, nuclear factor, interleukin 3, regulated; RevErbα, also known as NR1D1, nuclear receptor subfamily 1, group D, member 1; Rorα, RAR-related orphan receptor alpha; Pparg, peroxisome proliferator activated receptor gamma) were significantly changed in diabetes [33–36]. Although the master circadian system is located in the suprachiasmatic nucleus of the anterior hypothalamus, peripheral organs are also involved, including heart [37], liver [34], kidney, lung, and pancreas [35], indicating that dysfunction of circadian rhythms may be an underlying mechanism for DKD. Studies have investigated the circadian rhythms with DKD, but most of them mainly focused on blood pressure circadian rhythm; blood pressure circadian rhythm of CKD patients frequently shows a non-dipper pattern. The average 24-h, daytime, and nighttime blood pressure is elevated.

Figure 5. A miRNA-gene interaction network. Orange indicates upregulated genes and green indicates downregulated genes.
Table 5. Small molecule drugs predicted by Cmap database.

| Cmap name              | Mean | N  | Enrichment | P         | Percent non-null |
|------------------------|------|----|------------|-----------|------------------|
| Thioguanosine          | 0.729| 4  | 0.927      | 0.00004   | 100              |
| Withaferin A           | 0.727| 4  | 0.826      | 0.00145   | 100              |
| DL-thiorphan           | 0.71 | 2  | 0.942      | 0.0065    | 100              |
| 5230742                | 0.675| 2  | 0.941      | 0.00664   | 100              |
| Menadione              | 0.664| 2  | 0.935      | 0.00797   | 100              |
| Roxithromycin          | 0.651| 4  | 0.846      | 0.00008   | 100              |
| Clomipramine           | 0.65  | 4  | 0.801     | 0.00298   | 100              |
| Prestwick-559          | 0.62  | 3  | 0.775     | 0.02285   | 100              |
| Repaglinide            | 0.604| 4  | 0.791     | 0.00372   | 100              |
| Daunorubicin           | 0.575| 4  | 0.76       | 0.00627   | 100              |
| Quinostatin            | 0.569| 2  | 0.858     | 0.04097   | 100              |
| Procyclidine           | 0.558| 4  | 0.702     | 0.01637   | 75               |
| Hydrastine Hydrochloride| 0.547| 4  | 0.754     | 0.00702   | 100              |
| Lithothyronine         | 0.536| 4  | 0.655     | 0.03268   | 75               |
| Fluspirilene           | 0.533| 4  | 0.719     | 0.01253   | 100              |
| (+)-Isoprenaline       | 0.526| 4  | 0.741     | 0.00656   | 100              |
| Zimeldine              | 0.518| 5  | 0.759     | 0.00194   | 100              |
| Flunisolide            | 0.506| 6  | 0.608     | 0.01128   | 83               |
| MG-262                 | 0.504| 3  | 0.754     | 0.02944   | 100              |
| Meclozine              | 0.495| 5  | 0.667     | 0.01077   | 80               |
| Abamectin              | 0.489| 4  | 0.716     | 0.01325   | 75               |
| Bulomedil              | 0.487| 4  | 0.704     | 0.01593   | 75               |
| Cetirizine             | 0.484| 4  | 0.707     | 0.01528   | 75               |
| 15-delta prostaglandin J2| 0.481| 15 | 0.531     | 0.00024   | 80               |
| beta-escin             | 0.479| 6  | 0.649     | 0.00544   | 83               |
| Sulfamethoxazole       | 0.474| 5  | 0.57      | 0.04652   | 80               |
| Thiostrepton           | 0.473| 4  | 0.632     | 0.04579   | 75               |
| STOCK1N-35215          | 0.461| 4  | 0.711     | 0.04729   | 66               |
| PNU-0251126            | 0.456| 6  | 0.599     | 0.01327   | 83               |
| Resveratrol            | 0.452| 9  | 0.497     | 0.01369   | 77               |
| Bufexamac              | 0.431| 4  | 0.668     | 0.02682   | 75               |
| Furaltadone            | 0.427| 6  | 0.564     | 0.02543   | 66               |
| Verteporfin            | 0.424| 3  | 0.711     | 0.04719   | 66               |
| Tanespimycin           | 0.414| 62 | 0.432     | 0         | 69               |
| Pempidine              | 0.413| 5  | 0.632     | 0.01922   | 60               |
### Table 5 continued. Small molecule drugs predicted by Cmap database.

| Cmap name            | Mean | N  | Enrichment | P       | Percent non-null |
|----------------------|------|----|------------|---------|------------------|
| Clotrimazole         | 0.405| 5  | 0.583      | 0.03893 | 60               |
| Carteolol            | –0.41| 4  | –0.704     | 0.01585 | 75               |
| Iohexol              | –0.422| 4 | –0.693     | 0.0188  | 75               |
| Rotenone             | –0.422| 4 | –0.64      | 0.04008 | 75               |
| Isoflupredone        | –0.426| 3 | –0.796     | 0.01723 | 66               |
| Cefaclor             | –0.435| 4  | –0.661     | 0.02988 | 75               |
| Timolol              | –0.444| 4  | –0.651     | 0.03515 | 75               |
| Ethionamide          | –0.446| 3  | –0.74      | 0.03603 | 66               |
| 3-acetamidocoumarin  | –0.447| 4  | –0.755     | 0.00734 | 75               |
| Alpha-yohimbine      | –0.447| 3  | –0.73      | 0.04044 | 66               |
| Cefotiam             | –0.456| 4  | –0.773     | 0.00539 | 75               |
| Erythromycin         | –0.457| 5  | –0.667     | 0.00955 | 80               |
| Felbinicin           | –0.472| 4  | –0.81      | 0.00253 | 75               |
| Streptozocin         | –0.472| 4  | –0.806     | 0.00277 | 75               |
| Terazosin            | –0.483| 4  | –0.685     | 0.02158 | 75               |
| Fursultiamine        | –0.508| 4  | –0.637     | 0.04187 | 75               |
| Benzathine benzylpenicillin | –0.524| 4  | –0.639     | 0.04048 | 75               |
| Ambroxol             | –0.551| 4  | –0.687     | 0.02077 | 75               |
| Clorsulon            | –0.618| 4  | –0.829     | 0.00161 | 100              |
| Cefoperazone         | –0.622| 3  | –0.906     | 0.00162 | 100              |
| Sulmazole            | –0.633| 3  | –0.893     | 0.00234 | 100              |
| Vinblastine          | –0.73 | 3   | –0.937     | 0.00038 | 100              |

Mean – the arithmetic mean of the connectivity scores for corresponding instances; N – the number of instances; Enrichment – A measure of the enrichment of those instances in the order list of all instances; P – an estimate of the likelihood that the enrichment of a set of instances in the list of all instances in a given result would be observed by chance.

Nighttime blood pressure in the patients with DKD were all significantly higher than those of patients with non-DKD, and these blood pressure parameters were found to be significantly correlated with albuminuria [38,39]. No studies explored the circadian rhythm-related genes in renal tissues of DKD. The present study is the first to show that Arntl is significantly downregulated in the renal tissues of diabetic mice. Arntl encodes a basic helix-loop-helix/Per-Arnt-Sim transcription factor that forms a heterodimer with CLOCK and then binds E-box enhancer elements upstream to activate transcription of Period (Per1, Per2, and Per3) and Cryptochrome (Cry1 and Cry2) genes. Downregulation of Arntl leads to lower expressions of Period and Cryptochrome genes, followed by upregulating cellular proliferation and transformation related genes (Cdkn1a, cyclin-dependent kinase inhibitor 1A; Cyclin E1; Claudin 1 and 12; and sFRP1, and secreted frizzled-related protein 1), contributing to the lesion damages in the kidney [40]. Therefore, restoring normal circadian rhythm by altering the expressions of these genes may be a potential approach for treatment of diabetes and its subsequent DKD [41]. As anticipated, Arntl was significantly upregulated in diabetic mice after TSF treatment, suggesting TSF may exert therapeutical effects on DKD by restoring normal circadian rhythm.

In addition to genes, increasing evidence suggests miRNAs may also be important for the development of DKD by either degrading the target mRNAs or inhibiting their translation via binding to the 3'-untranslated regions (UTR). For example,
miR-21 was demonstrated to promote renal fibrosis in DKD by targeting SMAD7, followed by enhancing TGF-β1-induced epithelial-to-mesenchymal transition [42,43]; downregulated miR-451 leads to overexpression of large multifunctional protease 7 (LMP7), which promotes NF-κB-mediated inflammation in mesangial cells and progression of DKD [44]. Thus, inhibition of miRNAs may be an underlying mechanism for treatment of DKD, which has also been reported by several studies [45,46]. Accordingly, miRNAs that regulated our crucial genes were also predicted and compared with the differentially-expressed miRNAs. The results suggest that only the Arntl-related mmu-miR-669j was significantly differentially expressed in the 2 groups and it has not been reported previously in DKD, indicating mmu-miR-669j may be a new target we identified and needs further experiments to confirm.

Moreover, the small-molecule drugs were also investigated to explore a combined strategy or indirectly demonstrate the role of TSF for treatment of DKD. The results showed withaferin A, DL-thiorphan, and mendadenone may have potential similar to TSF for treatment of DKD. The treatment effects of some small-molecule drugs on diabetes have also been demonstrated in previous studies. For example, it was reported that withaferin-A treatment marginally reduced the body weight of ob/ob and db/db mice and improved glucose homeostasis, which was also Stat3-mediated [47].

Conclusions

Our study reveals that TSF may be an effective and safe alternative for treatment of DKD via inhibiting Ragagp1-stat5-mediated cell proliferation and restoring miR-669j-Arntl-related circadian rhythm. Further in vitro and in vivo studies are needed to confirm these conclusions, which may be our team’s future research focus.

Conflict of interest

None.

References:

1. Whiting DR, Guariguata L, Weil C, Shaw J: IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract, 2011; 94: 311–21
2. Parving H H, Lewis J B, Ravid M et al: Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. Kidney Int, 2006; 69: 2057–63
3. Packham D K, Alves T P, Dwyer J P et al: Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: Results from the Diametric (Diabetes Mellitus Treatment for Renal Insufficiency Consensus) database. Am J Kidney Dis, 2012; 59: 75–83
4. Fried L F, Emanuelle N, Zhang J H et al: Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med, 2013; 369: 1892–903
5. Akh L: Diabetic nephropathy—complications and treatment. Int J Nephrol Renov Dis, 2014; 7: 361–81
6. Fineberg D, Landeleitlaham K, Cooper M: Diabetic nephropathy: Diagnosis and treatment. Nat Rev Endocrinol, 2013; 9: 713–23
7. Ren F, Tang L, Cai Y et al: Meta-analysis: The efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy. Ren Fail, 2015; 37: 548–61
8. Li R, Xing L, Mu X et al: Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review. Drug Des Devel Ther, 2015; 9: 6275–83
9. Effertth T, Li PC, Konkimalla VS, Kaina B: From traditional Chinese medicine to rational cancer therapy. Trends Mol Med, 2007; 13: 353–61
10. Liu Y, Chen XX, Tang CW et al: Edible plants from traditional Chinese medicine is a promising alternative for the management of diabetic nephropathy. J Funct Foods, 2015; 14: 12–22
11. Xiao Y, Liu Y, Yu K et al: The effect of chinese herbal medicine on albuminuria levels in patients with diabetic nephropathy: A systematic review and meta-analysis. Evid Based Complement Alternat Med, 2013; 2013: 937549
12. Li P, Chen Y, Liu J et al: Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: A multicenter double-blind randomized placebo-controlled trial. PLoS One, 2015; 10: e0126027
13. Zhao H, Xin L, Zhao T et al: Tangshen formula attenuates diabetic renal injuries by upregulating autophagy via inhibition of PLZF expression. PLoS One, 2017; 12: e0171475
14. Zhao T, Sun S, Zhang H et al: Therapeutic effects of tangshen formula on diabetic nephropathy in rats. PLoS One, 2016; 11: e0147693
15. Hu J, Fan X, Meng X et al: Evidence for the involvement of JAK/STAT/SOCS pathway in the mechanism of Tangshen formula-treated diabetic nephropathy. Planta Med, 2014; 80: 614–21
16. Iriyarity RA, Hobbs B, Collin F et al: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics, 2003; 4: 249–64
17. Ritchie ME, Shipson B, Wu D et al: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 2015; 43: e47
18. Szklarczyk D, Franceschini A, Wyder S et al: STRING v10: Protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res, 2015; 43: D447–52
19. Kohl M, Wiese S, Warscheid B: Cytoscape: Software for visualization and analysis of biological networks. Methods Mol Biol, 2011; 696: 291–303
20. Bader GD, Hogue CW: An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics, 2003; 4: 2
21. Dweep H, Gretz N: miRWalk2.0: A comprehensive atlas of microRNA-target interactions. Nat Methods, 2015; 12: 697
22. Kang JH, Chae YM, Park KK et al: Suppression of mesangial cell proliferation and extracellular matrix production in streptozotocin-induced diabetic rats by Sp1 decoy oligodeoxynucleotide in vitro and in vivo. J Cell Biochem, 2008; 103: 663–74
23. Xu F, Wang Y, Cui W et al: Resveratrol prevention of diabetic nephropathy is associated with the suppression of renal inflammation and mesangial cell proliferation: Possible roles of Akt/NF-κB Pathway. Int J Endocrinol, 2016; 2014: 289327
24. Huang X, Su YK, Deng HC et al: Suppression of mesangial cell proliferation and extracellular matrix production in streptozotocin-induced diabetic mice by adiponectin in vitro and in vivo. Horm Metab Res, 2014; 46: 736–43
25. Corpet A, De KL, Toedling J et al: Asf1b, the necessary Asf1 isoform for replication licensing, is predictive of outcome in breast cancer. EMBO J, 2011; 30: 480–93
26. Paul PK, Rabaglia ME, Wang CY et al: Histone chaperone Asf1B promotes human iPS-cell proliferation via recruitment of histone H3.3. Cell Cycle, 2015; 15: 3191–202
27. Wang Z, Chen J, Zhong MZ et al: Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients. Cancer Chemother Pharmacol, 2017; 79: 535–43
28. Zeng S, Yu X, Ma C et al: Transcriptome sequencing identifies ANLN as a promising prognostic biomarker in bladder urothelial carcinoma. Sci Rep, 2017; 7: 3151
29. Zhou W, Wang Z, Shen N et al: Knockdown of ANLN by lentivirus inhibits cell growth and migration in human breast cancer. Mol Cell Biochem, 2015; 398: 11–19
30. Saigusa S, Tanaka K, Mohri Y et al: Clinical significance of RacGAP1 expression at the invasive front of gastric cancer. Gastric Cancer, 2015; 18: 84–92
31. Adrichem AJV, Wennerberg K: MgcRacGAP inhibition stimulates JAK-dependent STAT3 activity. FEBS Lett, 2015; 589: 3859–65
32. Gubin DG, Nelaeva AA, Uzhakova AE et al: Disrupted circadian rhythms of body temperature, heart rate and fasting blood glucose in prediabetes and type 2 diabetes mellitus. Chronobiol Int, 2017; 31: 1–13
33. Lebailly B, Boitard C, Rogner UC: Circadian rhythm-related genes: Implication in autoimmunity and type 1 diabetes. Diabetes Obes Metab, 2015; 17(Suppl. 1): 134–38
34. Ando H, Ushijima K, Yanagihara H et al: Clock gene expression in the liver and adipose tissues of non-obese type 2 diabetic Goto-Kakizaki rats. Clin Exp Hypertens, 2009; 31: 201–7
35. Bostwick J, Nguyen D, Cornelissen G et al: Effects of acute and chronic STZ-induced diabetes on clock gene expression and feeding in the gastrointestinal tract. Mol Cell Biochem, 2010; 338: 203–13
36. Motosugi Y, Ando H, Ushijima K et al: Tissue-dependent alterations of the clock gene expression rhythms in leptin-resistant Zucker diabetic fatty rats. Chronobiol Int, 2011; 28: 968–72
37. Young ME, Wilson CR, Razeghi P et al: Alterations of the circadian clock in the heart by streptozotocin-induced diabetes. J Mol Cell Cardiol, 2002; 34: 223–31
38. Li J, Wang F, Jian G et al: Analysis of 24-hour ambulatory blood pressure monitoring in patients with diabetic nephropathy. A hospital-based study. Clin Nephrol, 2013; 79: 199–205
39. Hansen HP, Rossing P, Tarnow L et al: Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy. Kidney Int, 1996; 50: 579–85
40. Gumz, Michelle L, Cheng et al: Regulation of cellular transformation genes by the circadian clock protein Per1 in the kidney. FASEB J, 2011; 25: ib0113
41. Wang K, Sun Y, Lin P et al: Liraglutide activates AMPK signaling and partially restores normal circadian rhythm and insulin secretion in pancreatic islets in diabetic mice. Biol Pharm Bull, 2015; 38: 1142–49
42. Mcclelland AD, Herman-Edelstein M, Komers R et al: miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. Clin Sci, 2015; 129: 1237–49
43. Wang JY, Gao YB, Zhang N et al: miR-21 overexpression enhances TGF-β1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Mol Cell Endocrinol, 2014; 392: 163–72
44. Sun Y, Peng R, Peng H et al: miR-451 suppresses the NF-kappaB-mediated proinflammatory molecules expression through inhibiting LMP7 in diabetic nephropathy. Mol Cell Endocrinol, 2016; 433: 75–86
45. Wang JY, Gao YB, Zhang N et al: Tongsinliu ameliorates renal structure and function by regulating miR-21-induced epithelial-to-mesenchymal transition in diabetic nephropathy. Am J Physiol Renal Physiol, 2014; 306: 486–95
46. Zhang L, He S, Yang F et al: Hyperoside ameliorates glomerulosclerosis in diabetic nephropathy by downregulating miR-21. Can J Physiol Pharmacol, 2016; 94: 1249–56
47. Lee J, Liu J, Feng X et al: Withaferin A is a leptin sensitizer with strong anti-diabetic properties in mice. Nat Med, 2016; 22: 1023–32